Kidney Cancer - Related Resources

Cochrane reviews

Some targeted agents with specified molecular targets may have clinically useful benefits over the previous standard of care for patients with advanced renal cancer but the role of targeted agents is not yet fully established Targeted Therapy for Advanced Renal Cell Carcinoma.

Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med 2010 Feb 18;362(7):624-34. [PubMed]
Bukowski R, Cella D, Gondek K, Escudier B, Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007 Jun;30(3):220-7. [PubMed]
Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008 Jan 15;65(2):123-31. [PubMed]
Lowentritt B, Phelan MW, Vanzijl PS, Philosophe B, Sklar GN. Venacavoscopy during nephrectomy for renal cell carcinoma with inferior vena caval thrombus. J Urol 2006 Aug;176(2):468-71. [PubMed]
Remzi M, Özsoy M, Klingler HC, Susani M, Waldert M, Seitz C, Schmidbauer J, Marberger M. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol 2006 Sep;176(3):896-9. [PubMed]

Primary/Secondary Keywords